A single-Arm Phase II Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-resistant MET high subjects with locally advanced or metastatic colorectal cancer with wild-type KRAS

Trial Profile

A single-Arm Phase II Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-resistant MET high subjects with locally advanced or metastatic colorectal cancer with wild-type KRAS

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Tivantinib (Primary) ; Cetuximab
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Feb 2016 Planned End Date changed from 1 Jun 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov.
    • 06 Jul 2015 Status changed from recruiting to active, no longer recruiting, as reported in ArQule media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top